All 9 /Events 0 /In The News 8 /Press Releases 1

NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson’s, ALS

Biospace

Read more
9 November 2022/by Webadm

Omega Funds leads £16m Series A round for NRG Therapeutics

Business Weekly
9 November 2022/by Webadm

NRG closes £16M series A to fund fight against neurodegenerative diseases

Bioworld

Read more
9 November 2022/by Webadm

GSK vets theorize that a mitochondrial target may unlock Parkinson’s and ALS treatments in new startup

Endpoints

Read more
9 November 2022/by Webadm

NRG Therapeutics Announces £16 million Series A to Advance Mitochondrial Therapeutics for Parkinson’s and ALS

£16 million Series A led by Omega Funds, to advance disease-modifying…
9 November 2022/by Webadm

NRG gearing up for series A to advance brain-penetrant PTP inhibitors

Bioworld

Read more
(behind a paywall)
31 August 2022/by Webadm

NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease

Cambridge Independent

Read more
7 July 2022/by Webadm

NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment

PMLive

Read more
1 July 2022/by Webadm

NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders

Labiotech

Read more
30 June 2022/by Webadm

NRG Therapeutics Announces International Scientific Advisory Board

Stevenage, UK, 30 March 2023 - NRG Therapeutics, Ltd., an innovative…

NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme

Stevenage, UK, 22 February 2023 - NRG Therapeutics, Ltd., an…

NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Gilles Ouvry Ph.D, appointed to newly created position of…

Case Study: R&D grant funding

BIA, UK BioIndustry Association Read more

Parkinson’s disease drug hunters think outside the α-synuclein box

Nature Biotechnology Read more (behind paywall)

NRG raises Series A funds for Parkinson’s and ALS therapy development

Pharmaceutical Technology Read more

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

Labiotech Read more

NRG announces £16m Series A for IND for Parkinson’s and ALS

PharmaPhorum Read more